Matthew Sussman, MA

Matthew Sussman, MA is VP of Modeling & Strategy Services at BHE. Matt has over 20 years of business-to-business consulting experience, including more than 13 years of experience in health economics and outcomes research. He has published a wide array of outcomes research studies (e.g., health economic models, burden-of-illness analyses, retrospective database analyses, systematic literature reviews) and has provided manufacturers with forward-thinking, strategic insights into the value of treatment interventions across therapeutic and disease areas. Matt has a deep knowledge of ICER’s value assessment framework, best practices, and evaluations, and has led numerous strategic initiatives revolved around ICER assessments. He is a member of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) and is an executive committee member of the ISPOR Boston chapter. Matt received his undergraduate degree in Business Administration from the University of Michigan Ross School of Business and a graduate degree in Economics from Boston University.


Should ICER Be NICE (or Not)?: A Prelude to Our ISPOR Glasgow Issue Panel

ISPOR’s 20th Annual European Congress in Glasgow is fast approaching, with the first plenary session scheduled for this Monday, November 6th. I will be attending as part of BHE’s team and am looking forward to the plenary sessions discussing the evolution of value in healthcare, including the increase in value-based care initiatives, the future of[…]


A Need for Alignment: How ICER's New Cost-Effectiveness Framework Compares with the Second Panel's Recommendations

Methodologists in the HEOR community have been busy over the past 9 months. In September 2016, the Second Panel on Cost-Effectiveness in Health and Medicine published a special communication in JAMA (and subsequent hardcover book) that sought to provide guidance for improving the quality of cost-effectiveness (CE) analyses. A few months later in[…]


ICER's New Cost-Effectiveness Threshold Raises 5 Major Questions

Early last month the Institute for Clinical and Economic Review (ICER) released a revised Value Assessment Framework for public comment based on feedback received from patients, clinicians, life science companies, and other stakeholders. While a majority of the proposed changes lacked real luster, there is one proposed change that pharma should[…]

Instant Health Data

Put reliable, rapid analytics in the hands of more people across your organization

Learn more about Panalgo

Get the story behind our work and our team.